Sunday, June 26, 2022

Insider Selling: Gibson Christopher, Recursion Pharmaceuticals Inc. [RXRX] Chief Executive Officer divested 2,500 shares

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Recursion Pharmaceuticals Inc. shares valued at $15,859 were sold by Gibson Christopher on Jun 02. At $6.34 per share, Gibson Christopher sold 2,500 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, Gibson Christopher sold 39,690 shares, netting a total of over 241,766 in proceeds. Following the sale of shares at $6.09 each, the insider now holds 516,268 shares.

Before that, Gibson Christopher had sold 2,500 shares from its account. In a trade valued at $16,095, the Chief Executive Officer traded Recursion Pharmaceuticals Inc. shares for $6.44 each. Upon closing the transaction, the insider’s holdings decreased to 2,500 shares, worth approximately $0.0.

As published in a research note from BofA Securities on April 18, 2022, Recursion Pharmaceuticals Inc. [RXRX] has been rated down from a Buy to a Neutral and the price target has been revised to $10. This represents a 14.4% premium over Wednesday’s closing price. Analysts at SVB Leerink downgraded the stock from ‘”an Outperform”‘ to ‘”a Mkt perform”‘ outlook in a report released in early March. As of September 21, 2021, Berenberg has initiated its “Buy” rating for RXRX. Earlier on May 11, 2021, SVB Leerink initiated its rating. Their recommendation was “an Outperform” for RXRX stock.

Analyzing RXRX’s Price Performance

On Wednesday, Recursion Pharmaceuticals Inc. [NASDAQ: RXRX] rose 2.15% to $8.56. The stock’s lowest price that day was $8.11, but it reached a high of $9.05 in the same session. During the last five days, there has been a surge of approximately 38.06%. Over the course of the year, Recursion Pharmaceuticals Inc. shares have dropped approximately -50.03%. Shares of the company reached a 52-week high of $18.23 on 01/05/22 and a 52-week low of $4.92 on 05/12/22. A 50-day SMA is recorded $6.43, while a 200-day SMA reached $13.42. Nevertheless, trading volume fell to 1.7 million shares from 1.3 million shares the previous day.

Support And Resistance Levels for Recursion Pharmaceuticals Inc. (RXRX)

According to the 24-hour chart, there is a support level at 8.10, which, if violated, would cause prices to drop to 7.63. In the upper region, resistance lies at 9.04. The next price resistance is at 9.51. RSI (Relative Strength Index) is 66.43 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.04, which suggests the price will increase in the coming days. Percent R is at 13.92%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.

Which companies own the most shares of Recursion Pharmaceuticals Inc. (RXRX)?

According to Baillie Gifford & Co. filings, the company currently owns 21,981,604 shares, which is about 13.42% of the total RXRX shares outstanding. The investor’s shares have plunged by -141,551 from its previous 13-F filing of 22123155.0 shares. With the completion of the buy, The Vanguard Group, Inc.’s stake is now worth $39,320,070. BlackRock Fund Advisors reduced a -1.64% interest valued at $36.09 million while Laurion Capital Management LP purchased a 663,561 stake. A total of 504,899 shares of Recursion Pharmaceuticals Inc. were bought by AllianceBernstein LP during the quarter, and 595,150 were bought by ARK Investment Management LLC. In its current portfolio, Platinum Investment Management Lt holds 2,136,604 shares valued at $13.08 million.

In terms of Recursion Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $16.00 in the next 12 months, up nearly 19.33% from the previous closing price of $8.38. Analysts anticipate Recursion Pharmaceuticals Inc. stock to reach $38.00 by 2022, with the lowest price target being $7.00. In spite of this, 5 analysts ranked Recursion Pharmaceuticals Inc. stock as a Hold at the end of 2022. On May 11, 2021, KeyBanc Capital Markets assigned a price target of “an Overweight” to the stock and initiated coverage with a $36.

Latest news

Related news


Please enter your comment!
Please enter your name here




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam